Pyoderma
7
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
29%
2 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
A Real-World Registry of Chronic Wounds and Ulcers
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma
Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma
Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460)
Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory